The Samuel Waxman Cancer Research Foundation is an international organization dedicated to curing and preventing cancer. The Foundation is a pioneer in cancer research, focusing on uncovering the causes of cancer and reprogramming cancer cells. Our mission is to eradicate cancer by funding cutting-edge research that identifies and corrects abnormal gene function that causes cancer and develops minimally toxic treatments for patients.

Through our collaborative group of world-class scientists, the Institute Without Walls, investigators share information and tools to speed the pace of cancer research. Since our inception in 1976, The Foundation has awarded more than $85 million to support the work of more than 200 researchers across the globe.
Dear friend,

Collaboration isn’t what it used to be. It’s better.

After 39 years of funding cutting-edge research by the brightest minds in cancer research, the Samuel Waxman Cancer Research Foundation (SWCRF) is proud to witness a landscape of research transformed by the model of collaboration we pioneered in 1976. Exciting new cancer therapies are emerging more frequently these days, powered by advances in technology and the quickened pace of investigation facilitated by information sharing.

SWCRF researchers are leading the way in bringing innovative treatments from the laboratory to the patient thanks to the support of our dedicated donors. The past year has seen promising clinical trials initiated for therapies developed by SWCRF investigators in a range of cancers. Researchers at Salk Institute, led by Ronald Evans, Ph.D., found that a synthetic derivative of vitamin D collapses the barrier of cells shielding pancreatic tumors, making them more susceptible to drugs and teamed up with the University of Pennsylvania on a trial testing the therapy in pancreatic cancer patients.

At Johns Hopkins University, our funded team of Stephen Baylin, M.D., Robert Casero, Ph.D., and Cynthia Zahnow, Ph.D., discovered genes that may predict tumors that evade detection from the immune system. Their discovery produced a clinical trial in lung cancer. Most recently, a trial conducted at Memorial Sloan Kettering Cancer Center showed promising results for a drug that targets a mutated enzyme that provokes AML. The therapy, based on the work of SWCRF researcher Ross Levine, M.D., corrects the genetic programming of AML cells much like the groundbreaking combination therapy developed by the SWCRF with the Shanghai Institute of Hematology that reprogrammed APL cells and remains the standard of treatment for this disease.

Although we are encouraged by these developments, we’re hardly resting on our laurels. As part of our continued efforts to cure cancer through collaboration, we’re augmenting our core categories of research funding with Aging & Cancer, a program that applies epigenetics to the investigation of the causes and effects of cancer in people over 50. Much of our currently funded research is applicable to this category and can lead to potential treatments for leukemia, prostate cancer and breast cancer.

You’ll be hearing more about this exciting new initiative in the months ahead. We once again thank you for your continued support of our winning team of cancer researchers.

Sincerely,

Michael Nierenberg
Chairman
Samuel Waxman, M.D.
Founder and CEO
Robert Kantor
President
YEAR IN REVIEW

MAY 6
On May 6, New York City’s most prominent and philanthropic women supported the SWCRF’s inaugural Ladies Who Lunch for a Cure benefit, which featured a fashion presentation by honoree Nicole Miller.

JULY 26
The SWCRF raised $400,000 for cancer research at the tenth annual A Hamptons Happening on July 26, which honored chef David Burke, Betsey Johnson and Paul Ridley.

NOV 13
The SWCRF relaunched its young professionals group, the Millennial Society, at an after-work mixer at the Empire Hotel on November 13.

MAY 12
The SWCRF honored Kenneth Anderson of Dana-Farber Cancer Institute and noted advocate Musa Mayer at its scientific symposium at Mount Sinai on May 12.

JULY 26
A Hamptons Happening honoree Betsey Johnson.

DEC 4
The 17th annual Collaborating for a Cure Gala raised $2.5 million for cancer research on December 4 at Cipriani Wall Street. The honorees were designers Cushnie et Ochs.

JULY 10
Philanthropic golfers congregated at the beautiful Creek Club in Locust Valley, NY on July 10 for the 32nd annual SWCRF golf tournament and dinner.

OCT 1 - OCT 31
Fashion designer Tadashi Shoji created a limited edition scarf as the centerpiece of his Pay it Forward fundraiser for SWCRF’s breast cancer research programs in October.

DEC 4
Reggae star Ziggy Marley performed at the Waxman Gala.
The field of cancer research is buzzing about something that the Samuel Waxman Cancer Research Foundation (SWCRF) has known for more than 30 years --- cancer cells don’t need to be destroyed when they can be reprogrammed to behave normally. Recent therapeutic innovations in leukemia are showing that the approach has great potential for changing how researchers tackle solving the puzzle that is cancer.

A recent article in *The New Yorker* detailed the promising results of a clinical trial conducted at Memorial Sloan Kettering Cancer Center for a new drug to treat acute myeloid leukemia (AML). The article, aptly titled *The Transformation*, traced the genesis of the drug, which targets a mutated enzyme called IDH-2 that creates a molecule that alters a cell’s genetic programming by switching off certain genes in the cell so it doesn’t mature. The cell multiplies wildly, resulting in AML. The treatment binds to the mutated enzyme and heads off the creation of the disruptive molecule, thereby allowing the cells to mature normally.

The article’s author, noted health care writer Dr. Jerome Groopman, likened this reprogramming of the cancer cell to the application of all-transretinoic acid (ATRA), a derivative of Vitamin A, to activate maturation of acute promyelocytic leukemia (APL) cells in the mid-1980s. This breakthrough therapy resulted from the research of Drs. Zhen-Yi Wang and Zhu Chen, working at Ruijin Hospital in Shanghai in collaboration with SWCRF founder and CEO Samuel Waxman, M.D., at Mount Sinai in New York City. Drs. Wang and Chen, who founded the Shanghai Institute of Hematology in 1987, published findings regarding a 1988 trial for ATRA in which 23 out of 24 APL patients went into remission. When patients experienced recurrence after treatment, the trio of researchers applied combination therapy to their strategy by adding arsenic trioxide as a secondary therapy, effectively curing the APL with a two-step process whereby the ATRA caused maturation of the leukemic cells and the arsenic trioxide led the cancer cells to self destruct through a process called apoptosis. This therapeutic approach increased the five-year survival rate for APL from 25 percent to 95 percent and remains the standard for treating the disease.

Although the AML drug and the APL therapy address different targets – the AML therapy heads off a mutated enzyme while the APL breakthrough treats a destructive hybrid protein --- their shared goal is changing cell behavior. The work of Dr. Ross Levine, a renowned expert in myeloid malignancies at Memorial Sloan Kettering Cancer Center and an SWCRF-funded researcher, laid the groundwork for the AML trial. Dr. Levine’s research examines the genetic basis of myeloid malignancies, with a specific focus on the role of dysregulated signaling and disordered epigenetic patterning in myeloid leukemogenesis and in therapeutic response. His team’s study of the role of mutations in the epigenetic modifiers in the transformation of blood cells helped bring the AML treatment from bench to bedside.

“The support from the SWCRF has allowed us to make new insights into the pathogenesis of TET2/IDH-mutant leukemias, and to perform preclinical studies of novel therapeutics which target DNA methylation and mutant IDH proteins which are now entering the clinic,” said Dr. Levine. “We are very excited by these results and grateful for the support. Moreover, the SWCRF’s Institute Without Walls has provided an exceptional collaborative network which allows us to rapidly progress our work and to collaborate to achieve biologic and clinical impact.”

Mutations and epigenetics are the key targets for investigation in Aging & Cancer, the SWCRF’s new research initiative examining cancer incidence among people over the age of 50. A recent article in *The New York Times* reported that strides in the treatment of heart illnesses have increased the probability of more people between 55 and 84 dying of cancer than heart disease. Although age-related cancer diagnoses occur most frequently after the age of 60, cancer-causing cellular
FROM BENCH TO BEDSIDE

MARTIN S. TALLMAN, M.D.
Chief of the Leukemia Service at Memorial Sloan Kettering Cancer Center, reflects on the impact of research on patient outcomes.

This trial parallels Dr. Waxman’s differentiation of APL cells by combining ATRA with arsenic trioxide in collaboration with the Shanghai Institute of Hematology. How do you view the impact of this breakthrough on cancer research through the years?

When you think about the way we treat leukemia today, in a way it’s not very elegant. We administer very intensive chemotherapy that is not able to distinguish between leukemia cells from healthy cells and kills every cell. We hope that the patient doesn’t suffer significant toxicities and wait for healthy blood cells to reestablish normal blood formation. But Dr. Waxman and his colleagues at the Shanghai Institute of Hematology identified the method of differentiation; instead of killing the malignant cells, the approach turned them into healthy, mature cells. It was a remarkable advance, a seminal observation in the therapy of hematological malignancies and we think this new therapy is similar and that the differentiation is an identical mechanism, which is why it worked so well.

The SWCRF is proud that the work of its funded researcher Dr. Ross Levine played a central role in this breakthrough. As someone on the front line of patient care, how would you describe the impact of foundation support for science today?

I think it’s absolutely critical. In acute and chronic leukemias, lymphoma and multiple myeloma, there has never been a time when so many more important discoveries are being made that are finally translating into improved outcomes and cures for patients. I think support from the Samuel Waxman Cancer Research Foundation and all foundations is critical if we’re going to continue to make important discoveries that we can translate from the laboratory to the clinic. We have so many drugs and combinations to test it’s mind-boggling. Ultimately, it’s the most exciting time in medicine not just for us but also for patients so this funding has never been more important.

mutations provoked by genetic and environmental factors can begin at 50 and build up over time. Current SWCRF-funded work relating to inflammation, stem cells and blood malignancies holds promise for new discoveries that can bring non-toxic therapies to this underserved population.

The Aging & Cancer program should benefit from a new collaboration between Israel and China that will examine the roles of two proteins in the onset of AML, the most common acute leukemia affecting adults whose incidence increases with age. Shai Izraeli, M.D., Sheba Medical Center at Tel Aviv University, and Sai-Juan Chen, M.D., Ph.D., the Shanghai of Hematology, both longtime funded SWCRF researchers, will serve as principal investigators in new research coordinated through a partnership between the Natural Science Foundation of China and the Israel Science Foundation and funded by the Chinese and Israeli governments. Drs. Izraeli and Chen aim to better understand the dynamics of transcription factors in the formation of AML.

“It’s very exciting to see SWCRF collaborators making strides around the world with their transformative work,” said SWCRF founder and CEO Samuel Waxman, M.D. “Our funded researchers are driving innovation in blood cancer investigation and their work is being recognized as leading science that is bringing us closer to a cancer cure.”

In patients who had, in general, relapsed or refractory disease that had failed other more conventional therapies and had few options, a significant percent of them achieved a true, complete remission and many achieved near complete remission. I know of several patients who achieved another remission with outpatient, oral drug therapy that was not very toxic and were able to go on to a transplant. This trial was a Phase 1 trial to find the optimal dose but we saw complete remissions very early, which was really striking and unusual in a Phase 1 trial. The next series of trials will be to combine this drug with intensive chemotherapy.

What is the demographic profile of the participants in the trial?

These were patients with quite advanced hematologic malignancies who had been treated with more conventional cytotoxic therapies and had failed to respond or had relapsed. About 20 percent had undergone transplants. Some had relapsed after transplants and some relapsed after six months of chemotherapy. There were roughly an equal number of men and women ranging between the ages of 33 and 90 with the average age being 67.

It is every cancer researcher’s goal to see their theories lead to effective patient therapies and Memorial Sloan Kettering’s recent clinical trial for an AML drug showed promising results. What were the findings?

In patients who had, in general, relapsed or refractory disease that had failed other more conventional therapies and had few options, a significant percent of them achieved a true, complete remission and many achieved near complete remission. I know of several patients who achieved another remission with outpatient, oral drug therapy that was not very toxic and were able to go on to a transplant. This trial was a Phase 1 trial to find the optimal dose but we saw complete remissions very early, which was really striking and unusual in a Phase 1 trial. The next series of trials will be to combine this drug with intensive chemotherapy.

What is the demographic profile of the participants in the trial?

These were patients with quite advanced hematologic malignancies who had been treated with more conventional cytotoxic therapies and had failed to respond or had relapsed. About 20 percent had undergone transplants. Some had relapsed after transplants and some relapsed after six months of chemotherapy. There were roughly an equal number of men and women ranging between the ages of 33 and 90 with the average age being 67.

This trial parallels Dr. Waxman’s differentiation of APL cells by combining ATRA with arsenic trioxide in collaboration with the Shanghai Institute of Hematology. How do you view the impact of this breakthrough on cancer research through the years?

When you think about the way we treat leukemia today, in a way it’s not very elegant. We administer very intensive chemotherapy that is not able to distinguish between leukemia cells from healthy cells and kills every cell. We hope that the patient doesn’t suffer significant toxicities and wait for healthy blood cells to reestablish normal blood formation. But Dr. Waxman and his colleagues at the Shanghai Institute of Hematology identified the method of differentiation; instead of killing the malignant cells, the approach turned them into healthy, mature cells. It was a remarkable advance, a seminal observation in the therapy of hematological malignancies and we think this new therapy is similar and that the differentiation is an identical mechanism, which is why it worked so well.

The SWCRF is proud that the work of its funded researcher Dr. Ross Levine played a central role in this breakthrough. As someone on the front line of patient care, how would you describe the impact of foundation support for science today?

I think it’s absolutely critical. In acute and chronic leukemias, lymphoma and multiple myeloma, there has never been a time when so many more important discoveries are being made that are finally translating into improved outcomes and cures for patients. I think support from the Samuel Waxman Cancer Research Foundation and all foundations is critical if we’re going to continue to make important discoveries that we can translate from the laboratory to the clinic. We have so many drugs and combinations to test it’s mind-boggling. Ultimately, it’s the most exciting time in medicine not just for us but also for patients so this funding has never been more important.
INVESTING IN HOPE FOR A DEADLY CANCER

“We have had the fortune to be funded by the SWCRF for the past five years. The SWCRF has allowed us to focus particularly on the treatment of one of the most aggressive malignancies known, called NUT midline carcinoma (NMC), a rare subtype of squamous cell cancer. The SWCRF has nurtured our small program that began with no treatment for this horrible disease, to now three clinical trials in North America using targeted inhibitors of the causative cancer protein, called BRD4-NUT. Now this disease, which promised a median survival of 6.5 months, has some hope of a more effective treatment. Although most foundations might be disinterested in a rare disease such as this, the SWCRF had the insight to realize that NMC really is the exception that has proved the rule for many other common cancer types. It turns out that the BRD4 part of the cancer protein in NMC also drives cancers such as leukemia and prostate cancer, and thus the inhibitors that have opened the door to targeted therapy of NMC are also potentially useful in these much more common diseases. We have the forward-thinking Dr. Samuel Waxman and the SWCRF team of world-class scientific advisors to thank for these steps forward in cancer treatment.”

TARGETING METASTASIS IN BREAST CANCER

My research focuses on how autophagy can be targeted to impede breast cancer progression and metastasis. Autophagy is a fundamental cellular recycling pathway (literally meaning “self-eating”) used by cancer cells to survive and thrive in stressful environments. Recently, we made the surprising discovery that autophagy also promotes the ability of tumor cells to secrete molecules that promote invasion. These findings challenge the long-held dogma that autophagy works as a metabolic adaptation pathway in cancer cells. Our SWCRF grant has proven invaluable in supporting this project and novel idea. We have since pinpointed that stromal fibroblasts, normal cells residing within a solid tumor that are critical for cancer growth, exhibit high levels of autophagy-dependent secretion. Upon specifically inhibiting autophagy in stromal cells, breast cancer progression is profoundly blocked in living organisms, presumably by “short-circuiting” a small environment that can produce tumors. These new findings are poised to completely transform how oncologists should apply autophagy inhibitors in the clinic. We are now testing the prediction that stroma-rich breast cancers will be uniquely susceptible to anti-autophagy drugs (e.g., hydroxychloroquine). In addition, the SWCRF “Institute Without Walls” has fostered exciting collaborations investigating the effects of how autophagy directs tumor dormancy, a critical but poorly understood aspect of metastatic progression.
Intrahepatic cholangiocarcinoma (iCCA) is an uncommon primary liver cancer with no accepted systemic therapy for patients whose tumors cannot be removed surgically. Thus, discovery of novel targets for therapies is a clear clinical unmet need. In this context we launched a comprehensive study by using cutting-edge technology with genome sequencing to search for novel targets amenable for molecular therapies. Our effort has been supported by the SWCRF since the beginning and we have established collaborations with academic centers in the United States and Europe. As a result, we have been able to propose a molecular classification of iCCA and to identify a novel oncogenic and targetable FGFR2 fusion, FGFR2-PPHLN1, and activating mutations in the ARAF oncogene. Our work supports translating our discoveries in the clinical arena by treating iCCA patients with FGFR2 fusion events with specific FGFR2 inhibitors. In addition, we established a landscape of druggable mutations of this tumor that are present in around 70 percent of iCCA patients and may benefit from targeted therapies. The funding received has given us the opportunity to stand at the front line in the fight against iCCA and significantly contribute to the genomic characterization and treatment of this deadly disease.
BLOOD MALIGNANCIES
Ravi Bhatia, M.D., UAB Comprehensive Cancer Center
Brad Cairns, Ph.D., University of Utah
Sai-Juan Chen, M.D., Ph.D., Shanghai Institute of Hematology
John D. Crispino, Ph.D., Northwestern University
Margaret Goodell, Ph.D., Baylor College of Medicine
Yongkui Jing, Ph.D., Mount Sinai Medical Center
David A. Jones, Ph.D., University of Oklahoma
Ross Levine, M.D., Memorial Sloan Kettering
Jonathan D. Licht, M.D., Northwestern University
Ari Melnick, M.D., Weill Cornell Medical Center
Warren Pear, M.D., Ph.D., University of Pennsylvania
Ruthbo Ren, M.D., Ph.D., Brandeis University
Samuel Waxman, M.D., Mount Sinai Medical Center
Arthur Zelent, Ph.D., University of Miami

BRAIN CANCER PROGRAM
Albert S. Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
Mark Lemmon, Ph.D., University of Pennsylvania
Kevan Shokat, Ph.D., University of California, San Francisco
William Weiss, Ph.D., University of California, San Francisco

BREAST CANCER PROGRAM
Albert S. Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
Stephen Baylin, M.D., Johns Hopkins University
Robert A. Casero, Ph.D., Johns Hopkins University
Jayanta Debnath, M.D., University of California San Francisco
Eduardo Farias, Ph.D., Mount Sinai Medical Center
Doris Germain, Ph.D., Mount Sinai Medical Center
Wilson Miller, M.D., Jewish General Hospital
Samuel Waxman, M.D., Mount Sinai Medical Center
Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D., Johns Hopkins University
Arthur Zelent, Ph.D., University of Miami
Ming-Ming Zhou, Ph.D., Mount Sinai Medical Center

CANCER STEM CELL PROGRAM
Julio Aguirre-Ghiso, Ph.D., Mount Sinai Medical Center
Nabeel Bardeesy, Ph.D., Massachusetts General Hospital
Stephen Baylin, M.D., Johns Hopkins University
Ravi Bhatia, M.D., UAB Comprehensive Cancer Center
Robert A. Casero, Ph.D., Johns Hopkins University
Margaret Goodell, Ph.D., Baylor College of Medicine
Robert A. Weinberg, Ph.D., Whitehead Institute for Biomedical Research
Cynthia Zahnow, Ph.D., Johns Hopkins University

CHILDHOOD AND YOUNG ADULT CANCERS
Albert Baldwin, Jr., Ph.D., University of North Carolina, Chapel Hill
James E. Bradner, M.D., Dana-Farber Cancer Institute
John D. Crispino, Ph.D., Northwestern University
Christopher A. French, M.D., Brigham and Women's Hospital
Shai Izraeli, M.D., Tel Aviv University
Mark Lemmon, Ph.D., University of Pennsylvania
Yang Shi, Ph.D., Boston Children's Hospital & Harvard Medical School
Kevan Shokat, Ph.D., University of California, San Francisco
Erwin G. Van Meir, Ph.D., Emory University School of Medicine
William Weiss, M.D., Ph.D., University of California, San Francisco

COLON CANCER PROGRAM
Ronald Evans, Ph.D., Salk Institute
Reuben Shaw, Ph.D., Salk Institute
Brad Cairns, Ph.D., University of Utah
David A. Jones, Ph.D., University of Oklahoma
IN MEMORIAM

KATHY SARNA

The Samuel Waxman Cancer Research Foundation remembers Kathleen “Kathy” Sarna, our dear friend and longtime supporter who passed away in March after complications from surgery for a brain tumor. Kathy, who along with her sisters Jane Stanczuk and the late Lucille Montrony ran the Three Strohm Sisters Family Foundation, was a force to be reckoned with in the quest to fund cancer research. Whether organizing one of the foundation’s popular fundraisers, tending to the daily needs of the organization or advocating for research though one-on-one interactions, Kathy could be counted on to get results. It is her tenacity, directness and unassuming charm for which she will be remembered. She overcame a challenging childhood to raise a loving family with her husband Richard Sarna, have a career in advertising, survive breast cancer and make an indelible mark in the search for a cancer cure. Growing up in the Greenpoint section of Brooklyn, Kathy was born the fourth child of Joseph and Mary Strohm. The Strohm siblings, including brothers Joe, Edward and Frank, lost their mother to tuberculosis and their father was killed in a workplace accident.

These tragedies required that they be separated and raised by various family members. As the years passed, Kathy and her siblings drifted apart but were brought together in the 1990s when it was discovered that she, Jane and Lucille all had breast cancer. The family rallied around them as the sisters beat their breast cancer and started their fundraising mission in 1999, raising more than one million dollars for research through their foundation, with much of it benefiting the work of the SWCRF in pediatric and breast cancer. We stand with the Sarna and Strohm families in mourning the loss of Kathy and remain dedicated to continuing her legacy of advocacy for cancer research in partnership with the Three Strohm Sisters Family Foundation.

EMILIO LAMA

The Samuel Waxman Cancer Research Foundation (SWCRF) remembers supporter E. Antonio Lama, a well-respected businessman and community leader in the Dominican Republic who passed away of lung cancer in December at the age of 69. Through hard work and determination, he built a diversified group of companies with interests in automotives, plastics and paint manufacturing, hospitality, finance, and real estate. His success, together with his humble and humorous style and philanthropic giving, earned him the respect and admiration of many.

He was always a very private person in all his contributions and in his personal life. Always present when help was needed, he would never hesitate for a good cause; however, he never had an interest in taking the credit. He created The Magna Foundation in 2007 in order to start contributing to society and sustainable development, through the business instead of in a private manner, a project that is being developed by his successors. Mr. Lama made several generous donations to the SWCRF through The Magna Foundation.

He was a loving father and husband, and his priority in life was always his family. He was a brave man and accepted every challenge life gave him with no fear, dignity and a positive attitude. This quality was confirmed by SWCRF Founder and CEO Samuel Waxman, M.D., who treated Mr. Lama in New York City. Mr. Lama is survived by his wife Doralise, to whom he was married for 40 years, and four children: a daughter, Paula, and three sons, Agustin Antonio, Antonio, and Jose Gabriel, who are working in the businesses he created, following his steps and legacy.
THANK YOU

The following donors have shared The Samuel Waxman Cancer Research Foundation’s vision and belief in collaboration by generously funding the Foundation’s Institute Without Walls in 2014.

$200,000+
Mr. and Mrs. Reuben Mark

$100,000-$199,999
Mr. and Mrs. Wesley Edens
Emerald Foundation, Inc.
Mr. and Mrs. Arminio Fraga
Mr. and Mrs. Michael B. Nierenberg
Ms. Mary Henry and Mr. Howard Rubin
The Skirball Foundation
Soros Fund Charitable Foundation
Bettina and Spencer Waxman

$50,000-$99,999
The Rose M. Badgeley Charitable Trust
Musa and Tom Mayer
Morgan Stanley
Three Strohm Sisters Family Foundation
Triple Negative Breast Cancer Research Foundation
Mr. and Mrs. Jeffrey Verschleiser

$20,000-$49,999
Access Securities
Anonymous
Bank of America
Jack and Florence Berlin Foundation
Mr. and Mrs. Christopher M. Callahan
Mr. and Mrs. Peter Cherasia
Laura and James DeMare
Dentons
Douglas Elliman Real Estate
Mr. and Mrs. Scott Eichel
Mr. and Mrs. Johan Eveland
Mr. and Mrs. Kenneth Fishel
Good Hill Partners
Mr. and Mrs. Steven Gordon
Mr. W. David Hinkelman
Mr. Adam Katz
Mr. and Mrs. Howard Kurz
Jay N. Levine and Tammy L. Levine Family Foundation, Inc.
Lily Pond Capital Management
Mr. Thomas Maxwell
Mr. and Mrs. Jeffrey Mayer
Mr. Matthew McQueen
Mr. and Mrs. Randal A. Nardone
Mr. and Mrs. Craig Overlander
Palm Bay International
Mr. Randy Reiff
And Andrew Sabin Family Foundation
Mara and Baron Silverstein
Alan B. Slifka Foundation
Mr. and Mrs. Andrew Sloves
Mr. Nicholas P. Smith
Mr. and Mrs. Joseph G. Steffa, Jr.
Tadashi Shoji
Mr. and Mrs. Laurence Tarica
Titan Advisors, LLC
Tsai Fan Yu Foundation
Ms. Dena K. Weiner and Mr. David Rozenholc
Mr. Lawrence Wosskow
$10,000-$19,999
Barclays North America
Mr. and Mrs. John D. Brewer, Jr.
BTIG, LLC
Cantor Fitzgerald Relief Fund Administration
Mr. Brian Caroselli
Mr. and Mrs. Matthew R. Chasin
Mr. Brian Chin
Mr. Steven Choran
Dale and Peter Claman
Credit Suisse
Mark and Trish Davies
Mr. Thomas Durkin
Mr. Jesse Elhai
EverBank
Hilary and Joseph Feshbach
The Fridolin Foundation
Mr. and Mrs. Paul Friedman
The G & A Foundation
Ms. Giselle Gerson
Dr. Roger Gilbert
Goldman Sachs & Co.
Mr. Jeff Gravelle
Alyssa and Cliff Greenberg
Mr. Robert M. Grillo
Mr. and Mrs. Marshall Insley
Mr. Gary Jacob
Jefferies LLC
Mr. Bernard Kaminsky
Mr. and Mrs. Gershon Kekst
The Litwin Foundation
Mr. Leonard Litwin
M & T Bank
Mr. and Mrs. Thomas Marano
Mr. Michael Mazzei
MFA Financial Inc.
Mr. Martin Migliara
Nomura
Marci and Glenn Pere
Susan & Elhu Rose Foundation, Inc.
Mrs. Leah P. Sanzari
Ms. Amanda Schumacher
The Robert Sillins Family Foundation, Inc.
Mr. Charles Sorrentino
Mr. and Mrs. Richard Spitz
Mr. and Mrs. Alan L. Tyson
Mr. James C. Weakley and Ms. Maria T. Poli
Mr. and Mrs. Joshua B. Weintraub
Norman and Rosita Winston Foundation
$5,000-$9,999
Mr. and Mrs. Joseph Ades
Alston & Bird
Lawrence and Joan Altman
Arlotta Enterprises, Ltd.
Ms. Christine Arlotta and Mr. Mario Pecoraro
Mr. and Mrs. William Arnold
Mr. and Mrs. Frederick Boos
Mr. George K. Brommer, III
Mr. Michael Commaroto
Ms. Georgine Culiffe
Ms. Barbara Digan-Zweig
Mr. and Mrs. Robert Eichler
Ms. Jayme Fagas and Mr. Paul Strauch
Mr. and Mrs. Robert Fishbein
Mr. Christopher Garvie
Ms. Jeanmarie Genirs and Mr. Paul Josling
The Marsha Lilien Gladstein Foundation
Hatteras Financial Corporation
Mr. Robert Hershy
Mr. Bobby Hotaling
JP Morgan
Ms. Suzanne Klein
Ms. Lisa Konsker
Mr. Geoffrey Kott
Connie and Harvey Krueger
Mr. Norman Levine
Mr. Alexander Libin
Mr. Seemant Menon
Dana and Michael Miller
Mr. and Mrs. Ira Nierenberg
Options Group
Park East Gynecology and Surgery, PC
Mr. William Procida
Mr. and Mrs. Robert J. Richter
Debbie and Gil Schwartzberg
Mr. Frank Y. Skibo
Iris and Michael Smith
Mr. and Mrs. Marc Spilker
Sun Capital Partners, Inc.
Mr. Steven L. Swarzman
Tiffany & Co.
Mr. and Mrs. Richard C. Volpe
Ruth Winkelmann Wender Foundation

THANK YOU
Mr. Mitchell Winter and Lisa Kassel
Jill and Bobby Zarin

$1,000-$4,999
Ms. Kathy L. Anderson
Anonymous
Ms. Selin Aran
Arent Fox, LLP
Mr. Zach Aronson
Mr. Max Baker
Ms. Marjorie Baldinger
Mr. and Mrs. Frederick W. Barney, Jr.
Penny and Steven Beberman
Mr. Michael Bebon
Mr. Ralph Bernstein
Mr. Jason Biegel
Biener Auto Group
Blue Slate, LLC
Mr. and Mrs. Jonathan W. Bonesteel
Ms. Jisook Choi
City Of Hope
Amy and Scott Claman
Debbie and David Cantor
Marilyn and Sonny Cohn
Mr. and Mrs. Phil Cedar
Chelten House Products, Inc.
Daniel and Rhonda Chestler
Ms. Jisook Choi
City Of Hope
Mr. and Mrs. Thomas A. Conway
Mr. Edward Conway
Mr. Noah Cooper
Mr. James Cox
Mr. Martin L. Coyne
Mr. Ryan Craft
Cushman & Wakefield Inc.
Cushnie Et Ochs
Mr. Apurva Dabholkar
D.B.D. Contracting, LLC.
Mr. Gary DePersia
Mr. Conrad Dequadros
Mr. Jeffrey Desind
Ms. Rosalind Devon and Mr. Sanford Batkin
Kim and Jordan Dickstein
Mr. David Dietche
Dr. and Mrs. Ethan Dmitrovsky
Mr. Thomas J. Doherty
Ms. Adina Dolfman
Mr. Christopher M. Dowd
Mr. and Mrs. John Draghi
Mr. Ryan Driscoll
Dr. Susan D. Grossman and Mr. Adam Sokoloff
Glenn and Eva Dubin
Mr. Trent Duprey
The Dwight Group
Dynamic Credit Management
Mr. and Mrs. Jim Egan
Ms. Blake Eger
The Charles Evans Foundation
Mr. Timothy P. Fallon
Mr. Evan Federman
Mr. and Mrs. Robert Feidelson
Mr. James Finkel
Dori and Michael Fishbin
Mr. Christopher Flanagan
Mr. David Flannery
Fragrance Group
Mr. and Mrs. James E. Frankel
Mr. Daniel Frommer
Ms. Carol Fuller Venezia
Mr. Kevin Gately
Gess Donor Fund, A Donor Advised Fund of Combined Jewish Philanthropies of Greater Boston, Inc.
The Thomas and William Gilbane Foundation
Ms. Susan Givens
Ms. Cheryl Glory
Mr. and Mrs. Alan J. Goldberger
Laurie and Jeff Goldberger
Ms. Marjorie Goldin
Ms. Adrienne Gordon and Mr. Gary Herman
Greenswich Associates
Mr. Jeff Gropper
Ms. Felicia Grumet and Mr. Mitchell Levine
Ms. Martha Gunderson
Ms. Mary P. Haggerty
Mr. Joel C. Haims
The Stephen P. Hanson Family Foundation, Inc.
Mr. and Mrs. James Harrington
Haskell Jewels
Mr. and Mrs. Robert Hecht
Mr. Robert Heffner
Mr. and Mrs. Dennis A. Herman
Mr. and Mrs. Patrick Higgins
High Five Foundation
Hilldun
Mr. and Mrs. Daniel J. Hoffman
Mr. Michael Hokin
Mr. Vincent Horcasitos
Horizon Group
Mr. Michael Huang
Dana and Michael Hubbe
Ms. Marie Ianniello
Mr. and Mrs. Stuart Israel
Mr. Max K. Jaeger
Evan and Florence Janovic
Mr. Steven Jeraci
Mr. Charles Jin
JMP Securities
Ms. Betsey Johnson
Mr. William H. Johnston
Ms. Katherine Jones
Mr. Mike Joo
Mrs. Shanna Joseph
Mr. and Mrs. Kenneth Joseph
Ms. Nurit Kahane and Mr. Werner Haase
Mr. Ian Kahn
Mr. and Mrs. Edward Kaminsky
Mr. and Mrs. Robert Kantor
Ms. Mary Y. Kantor
Marc and Jodi Kaplan
Karuna Foundation
Deena and Erik Katz
Ms. Tracey Keegan
Mr. and Mrs. Steven Keltz
Sanjeev Khanna
Mrs. Sharon Wilkes Kinberg and Mr. Robert Kinberg
Mr. and Mrs. David J. Klein
Kleinberg, Kaplan, Wolff & Cohen, PC
Mr. Craig Knutson
Mr. Paul Kolaj
Mrs. Karyn Kornfeld
Mr. and Mrs. Andrew Kramer
Mr. and Mrs. Norman Kramer
Mr. and Mrs. Eric L. Krifchier
Mr. Joseph La Delfa Jr.
Mr. and Mrs. Michael Labadorf
Mr. Carey F. Lathrop
Mr. and Mrs. Norman Lattman
David and Marcia Laviipour
Mr. and Mrs. Robert Lawrence
Dr. and Mrs. Albert M. Leftkovits
Mr. and Mrs. Eric Leinwand
Saul and Eleanor Lerner Foundation, Inc.
Les Chateaux
Ms. Janice T. Levites
Mr. Paul Levy
Dr. and Mrs. Jonathan D. Licht
Marilyn and Sam Linder
Mr. and Mrs. Avery Lipman
Mr. Cameron MacDougall
The David & Sondra Mack Foundation
Ms. Romy Malbin
Mr. and Mrs. Harvey Mallenent
Mr. and Mrs. Satish M. Mansukhani
Mr. and Mrs. Frederick Marcus
Massachusetts General Hospital Cancer Center
Ms. Susan Maude
Mr. and Mrs. Steve Mayer  
Mr. and Mrs. Charles McGuffog  
Mr. Justin McNeilus  
Media Storm, LLC  
Mr. Craig M. Meltzer  
Ellen and Rick Miller  
Eve and Stephen Milstein  
Mr. James W. Milton  
Mission Capital  
M’ODA ‘OPERANDI  
Mr. Peter Mondics  
Ms. Pamela Morgan and Mr. Michael Trokel  
Mr. and Mrs. Bob Munsey  
Mr. and Mrs. Stephen J. Muto  
Mr. and Mrs. Glenn Myles  
Mr. and Mrs. Ari Nathan  
Ms. Cynthia Neiditch  
Neiman Marcus Group, Inc.  
Mr. Jack N. Nuismer  
Mr. and Mrs. Salvatore L. Puliafico  
Robin Pzena  
Mr. Philip Radus  
Mr. and Mrs. Michael Putteruti  
Mr. Jerome Pickholz  
Mr. Darrin Pinkham  
The Plaza Hotel  
Jamie and Mark Pollack  
Ms. Jen B. Press  
William H. Prusoff Foundation  
Mr. and Mrs. Salvatore L. Puliafico  
Robin Pzena  
Mr. Philip Radus  
Mr. James T. Raazer  
Amit Rametra  
Ms. Rhonda Ramparas  
Raymond James Financial  
Mr. Richard Reda  
Tade Reen  
Ms. Rashaan Reid  
Mr. Darren Reinstein  
Mr. Nicholas Rentas  
Ms. Milena G. Resca and  
Mr. Tiziano Legnaro  
Revman International  
Mr. John Riconda  
Ms. Christina Rose  
Mr. Mark Rosen  
Dr. and Mrs. Alan Rosenfeld  
Mr. and Mrs. Louis Rosenfeld  
Dr. and Mrs. Larry Rosenthal  
Mr. and Mrs. Robert Rotanz  
Lewis and Wendy Rubin  
Dr. and Mrs. Steven Rubin  
Alice and Michael Rudell  
Mr. and Mrs. John Ryding  
Mr. Benny Salerno  
Mr. Phil Sarna  
Mrs. Edwin C. Scheurer  
Mr. Greg Schwab  
Mr. John Schwartz  
Schwartz & Company, LLP  
Mr. Nicholas Seminara  
Mr. John Semrai  
Rapaport Shalat Foundation  
Mr. and Mrs. Thomas Shea  
Meryl and Ken Sherman  
Dr. David M. Shipper  
Mr. and Mrs. Howard Shlafmizt  
Mr. and Mrs. Tony M. Shogren  
Mr. Justin Short  
Mr. and Mrs. Allen Siegel  
Mr. Richard Sigg  
Mr. Leon Silverman  
Mr. Michael Simon  
Ms. Kushmaotee Gujadhur and Mr. Gyan Sinha  
Mr. Gary M. Slutsky  
Mr. and Mrs. Walter Small  
Mr. Adam Smith  
Mr. Peter Smith  
The Sobel Family Foundation  
Mr. and Mrs. Michael Sokol  
Solow Realty & Development  
Company LLC  
South Coast Plaza  
Mr. Michael Stavros  
Ms. Diane Steiner  
Steven Madden, Ltd.  
Mr. Alex Stone  
Ms. Mary Stone and Mr. Channing Creecy  
Mr. Miles Stuchin  
Mr. and Mrs. Jay Sullivan  
The Tadashi Foundation  
Ms. Cynthia Temple  
Tenshore Realty  
Mr. Marc J. Toscano  
Tree of Life Foundation International  
Ms. Wendy Ull  
The Venable Foundation  
Mr. Christopher Verrillo  
Mr. Subramani Viswanathan  
Mr. Christopher Walcott  
Mr. Mike Wassong  
Dr. and Mrs. Samuel Waxman  
Mr. and Mrs. Scott Waxman  
Waxman Leavel Literary Agency  
WCBS  
Weill Cornell Medical College  
Ms. Adele Weiner  
Mr. and Mrs. Stephen Weinstein  
Mr. Andrew Weinstein  
Wells Fargo  
Mr. Aaron Welsh  
Mr. and Mrs. Paul Whitman  
Whitton-Spector Foundation  
Richard and Debra Wilpon  
Cindy and David Wittels  
Dr. and Mrs. Richard A. Wolff  
Mr. Adam Yamold  
The Janet Yaseen Foundation  
Mr. Harry You  

$500-$999  
10th Street Chiropractic  
All Star Security  
Warren and Hayley Alstodt  
Anita Wolfe Interiors  
Judith and Alan Appelbaum  
Bank of America United Way Campaign  
Baum - Essex  
Beachfront Property Management  
Ms. Kate Berg  
Mr. Ethan Biter  
Mr. James Blaceo  
Mr. Steven Boxer and Ms. Michelle Walker  
Ms. Sheri Bronstein  
Mr. Sean Callen  
Castle Oil Corporation  
The Charatan/Holm Family  
Foundation, Inc.  
Chardan Capital Markets  
Chef’s Warehouse  
Mr. and Mrs. Marvin Chudnoff  
Cireca Theranostics, LLC  
Richard Cohen, Inc.  
Mr. and Mrs. Jeffrey Cole  
Ms. Christina DeSimone  
Ms. Ellen L. Diamond  
Ms. Amelia Doggwalker  
Mr. and Mrs. Brad Egna  
Mrs. Maria E. English-Christensen  
Dr. and Mrs. Bob Federman  
Stefanie and Paul Feidelson  
Mr. Bradley Fishel  
Mr. Adam Foster  
Ms. Nelsa Gidney  
Mr. and Mrs. Robert J. Goldstein  
Ms. Lucia Hwong Gordon  
Grandstand Sports and Memorabilia, Inc.  
The Greenwald Family  
Merri and Barry Grieff  
Dr. Samuel Guillory  
Gullo Specialty Foods  
Jane and Lowen Hankin  
Mr. Jon Hansburg  
Mr. and Mrs. Robert Harrison  
Mr. and Mrs. Howard Haykin  
Mr. S. Stanley Herman  
Sandy and John Horvitz
A NOTE TO OUR SUPPORTERS
We have carefully reviewed all gifts made to the Samuel Waxman Cancer Research Foundation to ensure each gift is properly recognized. The Thank You list includes all gifts made between January 1, 2014 and December 31, 2014. Gifts mentioned exclude in-kind donations and multiple year pledges.

We make every effort to follow the donor’s preferences when compiling the annual report list. If you would prefer to have your name listed differently in the future, please let us know. If we have made a mistake, we sincerely apologize for our error and ask you to bring it to our attention. Please contact Jay Camp at 646-398-5260 so the record may be corrected. Thank you.

Photo credits:
Gala: Rebecca Weiss Photography and Patrick McMullan
Hampton’s Happening: Society-in-Focus
Golf tournament: Jerry Lacay
Scientific Symposium: Andrei Jackamets
Ladies Who Lunch for a Cure: Lin Pernille

GIFTS WERE MADE IN HONOR OR IN MEMORY OF
Mr. Peter Bartlett  
Sandy Biber  
Brother of Anne Bushinger  
Mrs. Dale Claman  
Mr. Louis Cochet  
Mr. Avi Concool  
Ms. Susan Davis  
Ms. Signora Germana Donato-Mangiarotti  
Ms. Anna Elman  
Ms. Ruth Finley  
Mr. Robert Fishbein  
Mr. Mark J. Fizulich  
Mr. Howard Fuss  
Chet and Nancy Gilbert  
Ms. Blanche Gishe  
Mr. Larry Goichman  
Mr. Abner J. Golieb  
Ms. Sylvia Hoffman  
Mr. Arthur E. Imperatore, Sr.  
Mr. Gary Jacob  
Mr. Sandy Kadish  
Mr. Bernard Kaminsky  
Mr. Irwin Klein  
Mr. Herbert Kramer  
Mrs. Marcia Lavipour  
Elin and Michael Nierenberg  
Mr. Joseph R. Paolino, Sr.  
Ms. Jessie Pek  
Ms. Bernette B. Plump  
Ms. Nancy Weintraub

Mr. Shawn J. Raysor  
Ms. Katherine R. Ridley  
Ms. Sindy Schurman Rubenstein  
Mr. Charles Schaffran  
Ms. Emma Senders  
Mr. Mayer Siegel  
Mr. Jack Skoog  
Mr. David S. Taub  
Ms. Kathy Tipper  
Mr. Irving Toplin  
Ms. Melanie Twomey  
Mr. Jack Waxman  
Mrs. Marion Waxman  
Dr. Samuel Waxman  
Ms. Nancy Weintraub

Mr. James Iorio  
Mr. and Mrs. Bill Joseph  
Mr. Laurence J. Kirschbaum  
Ms. Karen Klopp  
Mr. and Mrs. Matthew Knopman  
Mr. Steven P. Kornblatt  
Mr. Morris Kramer  
Mr. and Mrs. Jerry Kremer  
Mr. and Mrs. Burt Kremsky  
Mr. Charles Kurz  
La Force & Stevens  
Oscar and Lillian Lama  
Mr. and Mrs. Shawn P. Landau  
Mrs. Brenda J. Lane  
Susan and Bob Lane  
Mrs. Phyllis Leventhal  
Mr. and Mrs. Laurence R. Levy  
Jamie Lichtman  
Mr. and Mrs. Alan Lieberman  
The Loewy Foundation  
Mr. Timothy Madden  
Carol and Peter Mc Niemey  
Mr. Greg McGuffin  
Mr. Steve Montemarano  
Morgan Stanley Annual Appeal  
Mr. Brian Moses  
Mr. Erik W. Muller  
Mr. Roderick J. Murray  
Neisloss Family Foundation  
David and Leonore Nichols  
Norsic & Sons  
Mr. Ryan Oded  
Outdoor Solutions Group  
Ms. Grace Park  
Mr. Allan L. Pashcow  
Mr. Dennis B. Poster  
Mr. Jawad Rathore  
Mr. John Rice  
Mr. Kevin J. Richardson  
Mr. Paul Ridley  
RMS Fashions, Inc.  
The Craig & Flori Roberts Foundation  
Mr. and Mrs. Eric Rothfeld  
Royal Abstract of New York  
Mr. and Mrs. Charles Schaffran  
Ms. Lauren Sedbon  
Ms. Cassandra Seidenfeld and Mr. Robert Lyster  
Mr. and Mrs. Martin Shafiroff  
Mr. and Mrs. Jerome Shapiro  
The Shikiar Family Foundation  
Mr. Richard Siegal  
Mr. John Siegal  
Mr. and Mrs. Steven Siegel  
Mr. Harlan H. Simon  
Ms. Lisa Simonsen  
Mr. David Smith  
Mr. and Mrs. Richard Solomon

Mr. David Spector  
Mr. Neal Sroka  
Stamford Tent  
Mel and Sheila Stecker  
Mr. Michael Steffis  
Mr. and Mrs. Michael E. Stoll  
Mr. Jerry Sunday  
Susan Oberg Investments, Ltd.  
Mr. Wayne Talsky  
Mr. Robert Tarlowe  
Mr. Peter Tipograph  
Mr. Russell Tipper  
Mr. Christopher Tkac  
Ms. Sharon M. Tomao  
Mr. Howard H. Tomlinson  
Ms. Robin Von Bokhorst  
Mr. and Mrs. Michael Walmak  
Mr. Thomas Watts  
Ms. Evelene Wechsler  
Mr. and Mrs. Joel Wernick  
Mr. and Mrs. Lawrence Wilens  
Whispering Bells Foundation  
Fan Xing  
Kristina and Marshall Younger  
Mr. Gary Zecher

Mr. and Mrs. Marion Waxman  
Dr. Samuel Waxman  
Ms. Nancy Weintraub
## FINANCIAL STATEMENT

*(July 1, 2013 – June 30, 2014 audited)*

### REVENUE

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Contributions</td>
<td>$245,000</td>
</tr>
<tr>
<td>Program Grants</td>
<td>$1,466,000</td>
</tr>
<tr>
<td>Event Income</td>
<td>$1,211,000</td>
</tr>
<tr>
<td>Investment Income</td>
<td>$65,000</td>
</tr>
<tr>
<td><strong>Total Revenue</strong></td>
<td><strong>$2,987,000</strong></td>
</tr>
</tbody>
</table>

### EXPENSE

<table>
<thead>
<tr>
<th>Category</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Program Services</td>
<td>$3,241,000</td>
</tr>
<tr>
<td>Fundraising</td>
<td>$222,000</td>
</tr>
<tr>
<td>Management and General</td>
<td>$556,000</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td><strong>$4,019,000</strong></td>
</tr>
</tbody>
</table>

### SURPLUS/(DEFICIT)

**($1,032,000)**
SAMUEL WAXMAN CANCER RESEARCH FOUNDATION

FOUNDATION TEAM

Founder and Chief Executive Officer – Samuel Waxman, M.D.
Chief Scientific Officer – Jonathan Licht, M.D.
Chief Mission Officer – Alan Rosmarin, M.D.
Director of Special Events – Bridget Stein
Director of Marketing and Communications – Edgar Trinidad
Director of Development – Boris Cooper
Database Manager – Jay Camp
Office Manager – Amanda Aronson
Development Coordinator – Erica Linden-Fineberg
Scientific Advisory Board – Steven D. Gore, M.D., Lorraine Gudas, Ph.D.,
Ramon Parsons, M.D., Ph.D., Nancy Speck, Ph.D., Hua Yu, Ph.D.

FOUNDATION BOARD

Chairman – Michael Nierenberg
President – Robert Kantor
Vice Presidents – Spencer Waxman, Dena K. Weiner
Treasurer – Thomas A. Conway
Secretary – Laurie L. Schaffran
Board of Directors – Dale Claman, Kenneth Fishel, James E. Frankel, Gary Gladstein,
Clifford Greenberg, Dennis A. Herman, Linda Herman, David Hinkelman, Alissa Jacob,
Gary Jacob, Howard Kurz, Matthew Lyons, Riva Ariella Ritvo-Slfk, Howard Shlafmitz,
Tony M. Shogren, Baron Silverstein, David S. Taub+,
Samuel Waxman, M.D.
Honorary Board – Maureen Cogan, Martin L. Coyne, Mary Kantor, Abner Levine +,
Mildred Levine, Susan W. Rose, Alan P. Safir *, Joan A. Safir *, Edwin C. Scheurer +,
Alfred J. Seaman +, Zena Wiener
Chairman’s Council – Lawrence Altman, Peter Claman, Ruth Finley, Arminio Fraga,
Betsey Johnson, Costas Kondylis, Thomas Marano, J. Jay Mautner, Tadashi Shoji,
Bernard Sillins

* Past Chair  + Deceased